MedTrace Logo

Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma

NCT02743819 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-06-10

Study results available
· View outcomes & findings →

Summary

Phase II study evaluating the benefit of the combination of anti-PD1 (pembrolizumab) and anti-CTLA4 (ipilimumab) antibodies in advanced melanoma. The study will determine the response rate of the combination and evaluate other clinical parameters such as progression-free survival and safety of the combination following anti-PD1/L1 antibody. The study will also provide the opportunity to investigate blood or tumor based factors that may predict response to anti-PD1 antibody in combination with anti-CTLA4.

Conditions

Interventions

DRUG

Pembrolizumab

Pembrolizumab given every 3 weeks (200 mg) by IV infusion.

DRUG

Ipilimumab

Ipilimumab given every 3 weeks (200 mg) by IV infusion for total of 4 doses.

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Thomas Gajewski, M.D. · University of Chicago

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-28
Primary Completion
2022-06-01
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02743819 on ClinicalTrials.gov